Bone marrow treatment gets boost

In January I mentioned Apocell from Israeli biotech Enlivex, which prevents GVHD rejection of bone marrow transplants. Now, the treatment has received US FDA “orphan” status due to its importance and lack of alternatives for treating the unwanted autoimmune response.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *